OBJECTIVES: To describe the savings generated in a Clinic for Integrated Care of Immune-mediated Skin Disorders (CLIPSO).

METHODS: a descriptive cross-sectional study, in patients with immune-mediated skin disorders (psoriasis, hidradenitis suppurativa, urticaria, and atopic dermatitis) attended at CLIPSO between January 2021 and June 2022. Patients were evaluated by dermatologists and medical experts to define the most appropriate therapy for the patient. We defined savings as the fact of establishing a more economical therapy, decreasing the doses or increasing the frequency of the drug according to the clinical response of the patient, total suspension of treatment due to disease control, switching to biosimilar drugs, and avoidability of starting unnecessary biologic treatment. Univariate analysis is performed detailing summary measures such as central tendency, dispersion, and position. The R Core Team (2019) statistical package was used.

RESULTS: During the period evaluated, 152 patients were identified, mainly psoriasis (57.2%), 30.3% urticaria, 7.2% atopic dermatitis, 5.3% hidradenitis suppurativa, which generated a total saving of 395644 USD. 28.3% were due to frequency spacing, 23.0% total discontinuation of the biologic, 19.7% avoidability of initiation of biologic therapy, 15.8% chance of treatment, 11.8% dose adjustment, and 1.3% switch to biosimilar drug. The drugs managed were mainly 34.92% Omalizumab, 19.84% Adalimumab, 10.32% Dupilumab, 6.35% Etanercept, 4.76% Ustekinumab, 4.76% Ixekizumab and 2.38% Secukinumab.

CONCLUSIONS: CLIPSO generates a relevant economic impact on the appropriate prescription and staging of biologic therapies for patients with immune-mediated skin disorders.